{
  "version": 3,
  "created_at": "2026-07-09T21:33:25.579Z",
  "task_summary": "Build the company, platform, and regulatory strategy + VC pitch deck for a personalized EoE tolerance-vaccine biotech",
  "agents": [],
  "phases": [
    {
      "name": "Plan",
      "delegations": [
        {
          "steps": [
            {
              "title": "Company identity & founding thesis",
              "description": "Propose 3 company name candidates with rationale (evoking antigen-specific tolerance / re-education of the immune system, not generic bio-words), recommend one, and lock a tagline. Write a brand brief covering mission, founding thesis (patient-scientist origin; tolerance vs. lifelong suppression), positioning statement, and a simple visual identity concept (palette, motif). Save `company_brand_brief.md` and a title/brand hero figure `brand_hero.png`."
            },
            {
              "title": "Platform architecture — clinic to vaccine",
              "description": "Define and name the end-to-end platform: patient biopsy + blood → HLA-II typing + food-reactive peTH2 profiling (the existing dx assay) → per-patient epitope core selection → construct assembly (shared MHC-II backbone + swappable peptide cassette) → nanoparticle formulation → release → dose. Render a publication-grade horizontal workflow figure `platform_architecture.png` and a companion 'personalization decision tree' figure showing how a walk-in patient is routed (off-the-shelf match vs N-of-1). Save both plus `platform_spec.md` describing turnaround, inputs/outputs, and the tolerance mechanism (Signal-1 anergy + multivalent Tr1/IL-10 induction)."
            },
            {
              "title": "Population-coverage analysis (HLA × food)",
              "description": "Quantify how a menu of MHC-II backbones × food antigens covers the EoE patient population. Pull HLA-DRB1 allele frequencies for relevant populations (US/European) and combine with EoE food-trigger prevalences (milk ~60%, wheat ~40%, soy ~30%, egg, etc.). Compute cumulative patient coverage as the construct library grows (DR7 alone → +DR15/DR3/DR4/DR13 …). Produce `coverage_analysis.csv` and a cumulative-coverage curve figure `population_coverage.png` showing what fraction of patients an N-backbone × M-food catalog reaches, and where the N-of-1 arm picks up the tail."
            },
            {
              "title": "Regulatory strategy",
              "description": "Write `regulatory_strategy.md`: FDA pathway for an antigen-specific tolerance biologic. Cover orphan-drug designation, Fast Track / Breakthrough / RMAT eligibility, and the platform-vs-individualized regulatory framing with real precedents — teplizumab/Tzield (tolerance disease-modification), individualized neoantigen vaccines (mRNA-4157, autogene cevumeran) and FDA's individualized-product / master-file thinking, and autologous platform-IND models. Address CMC per personalization tier, the biopsy/blood companion-diagnostic (CDx) angle, IND-enabling package mapped from the existing preclinical roadmap, and the Hill/Spergel food-antigen T-cell-assay patent as a freedom-to-operate / licensing item. Include a phase-by-phase regulatory timeline table."
            },
            {
              "title": "Market & competitive analysis",
              "description": "Build `market_analysis.md` + `market_model.csv` and three figures: (1) TAM/SAM/SOM funnel for US/EU EoE (prevalence → diagnosed → biologic-eligible → serviceable), (2) competitive 2×2 positioning (mechanism specificity vs. durability) placing dupilumab, cendakimab, tezepelumab, budesonide, PPIs vs. our tolerance vaccine, (3) cumulative cost-of-care over 10 years: lifelong biologic (~$40k/yr) vs. one-and-done tolerance induction. Ground competitors in the retrieved 2025–2026 landscape; state all assumptions explicitly."
            },
            {
              "title": "Financial model & value-inflection milestones",
              "description": "Replace the hackathon-scale budget with a realistic company financing plan. Build `financial_model.csv`: seed round sizing and use-of-proceeds to hit IND + Phase 1 readout, then Series A to Phase 2. Produce a use-of-proceeds figure `use_of_proceeds.png` and a value-inflection / milestone Gantt `milestone_timeline.png` (seed → IND → FIH → PoC), each milestone tagged with the de-risking it delivers. State the ask (headline $ and what it buys)."
            },
            {
              "title": "VC pitch deck",
              "description": "Assemble a ~16–18 slide VC-facing deck as `<Company>_VC_Pitch_Deck.pptx` and a self-contained `<Company>_VC_Pitch_Viewer.html`: title/founder story, problem & unmet need, why-now, the platform, the science + GPU-validation data (ipTM ≥0.87, tetramer-validated dairy anchor), personalization & population coverage, market, competition, business model, regulatory strategy, roadmap/milestones, IP & FTO, team, the ask + use of proceeds, vision. Embed the figures from prior steps. Keep claims honest (computational priors vs. validated anchor) and include a disclaimer slide."
            },
            {
              "title": "Executive one-pager & bundle",
              "description": "Write a VC teaser one-pager `executive_onepager.md` (problem, solution, traction/validation, ask) suitable for cold outreach, and bundle all deliverables into `company_launch_bundle.tar.gz`. Provide a closing README mapping each artifact to its use in fundraising."
            }
          ]
        }
      ],
      "id": "phase-0"
    }
  ],
  "desired_outputs": [
    "Company brand brief (name, mission, thesis, positioning)",
    "End-to-end platform architecture figure(s)",
    "Population-coverage analysis (HLA×food) with figure",
    "Regulatory strategy document",
    "Market & competitive analysis with figures",
    "Financial model + milestone/value-inflection timeline",
    "VC pitch deck (PPTX + HTML viewer)",
    "Executive one-pager / teaser"
  ],
  "feasibility": {
    "rationale": "Strong existing foundation in this project (9-construct GPU-validated pMHC-II panel, NP architecture, food-trigger diagnostic, preclinical roadmap). This work reframes that science into a fundable company: name/brand, an end-to-end clinic-to-vaccine platform, a population-coverage analysis, a regulatory strategy grounded in real precedents, a market/competitive analysis against the current EoE pipeline, a realistic financial model, and a VC-facing pitch deck. All analytic pieces (HLA×food coverage, market sizing, cost-over-time) use publicly available frequencies and pricing; design/strategy pieces are grounded in the retrieved landscape and cited precedents.",
    "confidence": "high"
  }
}